Outcome of Board Meeting

October 20, 2026 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Dalal Bandra (E), Mumbai-400051 Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Outcome of Board Meeting – Orchid Pharma Limited (“the Company”) Dear Sir/Madam, With reference to the captioned subject and pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), as amended read with SEBI Master Circular no. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. October 20, 2026 (commenced at 11:00 A.M. (IST) and concluded at 11:50 A.M. (IST) has, inter-alia, considered and approved proposal (as ‘Enabling Resolution’) to explore the potential market opportunities, in the best interest of the Company, for raising of funds by way of issue of equity shares or any other eligible securities or instruments, including fully or partly convertible debentures, by way of qualified institutions placement, private placement, public issue of equity shares and/or debt securities, preferential issue or through any other permissible mode, or any combination thereof, as may be considered appropriate, subject to such statutory and regulatory approvals as may be required, including the approval of the members of the Company, wherever applicable, and such other approvals, permissions and consents as may be necessary, for an indicative amount of upto Rs. 600 Crores (Rupees Six Hundred Crore Only). The applicable details pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time (“SEBI Circulars”), with respect to enabling approval granted by the Board for raising of funds is enclosed herewith as Annexure ‘A’. You are requested to take the submission on record. Thanking You, For Orchid Pharma Limited Kapil Dayya Company Secretary & Compliance Officer Mem. No.- F10698 Encl. as above Annexure- A Information as required under Regulation 30 - Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026 Particulars Details Type of securities proposed to be issued (viz. The Board of Directors of the Company has equity shares, convertibles etc.); and passed an Enabling Resolution, to explore the available market opportunities, for raising of funds by way of issue of equity shares or any other eligible securities or instruments, including fully or partly convertible debentures, by way of qualified Type of Issuance (further public offering, institutions placement, private placement, rights issue, depository receipts (ADR/GDR), public issue of equity shares and/or debt qualified institutions placement, preferential securities, preferential issue or through any allotment etc.) other permissible mode, or any combination thereof, as may be considered appropriate, subject to such statutory and regulatory approvals as may be required, including the approval of the members of the Company, Total number of securities proposed to be wherever applicable, and such other issued or the total amount for which the approvals, permissions and consents as may securities will be issued (approximately) be necessary, for an aggregate amount of up to Rs. 600 Crores (Rupees Six Hundred Crores), therefore the required information is not available as on date. Any cancellation or termination of proposal Not Applicable for issuance of securities including reasons thereof